Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

AC Immune SA (ACIU)

2.4   -0.19 (-7.34%) 09-24 14:42
Open: 2.52 Pre. Close: 2.59
High: 2.65 Low: 2.34
Volume: 59,401 Market Cap: 200(M)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.66 - 2.67 2.67 - 2.68
Low: 2.3 - 2.32 2.32 - 2.33
Close: 2.37 - 2.4 2.4 - 2.42

Technical analysis

as of: 2022-09-23 4:21:56 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 3.57     One year: 4.12
Support: Support1: 2.29    Support2: 1.91
Resistance: Resistance1: 3.06    Resistance2: 3.52
Pivot: 2.7
Moving Average: MA(5): 2.53     MA(20): 2.8
MA(100): 3.16     MA(250): 4.18
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 21.2     %D(3): 18.7
RSI: RSI(14): 35.3
52-week: High: 8.14  Low: 2.05
Average Vol(K): 3-Month: 47 (K)  10-Days: 43 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ACIU ] has closed above bottom band by 0.7%. Bollinger Bands are 23.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 21 Sep 2022
AC Immune (NASDAQ:ACIU) Research Coverage Started at StockNews.com - MarketBeat

Sat, 17 Sep 2022
Short Interest in AC Immune SA (NASDAQ:ACIU) Drops By 18.6% - MarketBeat

Thu, 01 Sep 2022
2022-09-01 | NDAQ:ACIU | Press Release | AC Immune SA - Stockhouse

Wed, 31 Aug 2022
AC Immune SA's (NASDAQ:ACIU) last week's 11% decline must have disappointed private equity firms who have a significant stake - Simply Wall St

Thu, 11 Aug 2022
AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer’s and Parkinson’s Diseases - Yahoo Finance

Fri, 22 Jul 2022
AC Immune Announces Upcoming Presentations at the Alzheimer's Association International Conference - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 83 (M)
Shares Float 33 (M)
% Held by Insiders 52 (%)
% Held by Institutions 18.2 (%)
Shares Short 414 (K)
Shares Short P.Month 488 (K)

Stock Financials

EPS -1
EPS Est Next Qtl -0.13
EPS Est This Year -0.63
EPS Est Next Year -0.73
Book Value (p.s.) 2.4
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -23.9
Return on Equity (ttm) -38.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.75
Sales Per Share 0
EBITDA (p.s.) -0.96
Qtrly Earnings Growth 0
Operating Cash Flow -75 (M)
Levered Free Cash Flow -48 (M)

Stock Valuations

PE Ratio -2.41
PEG Ratio 0
Price to Book value 1
Price to Sales 0
Price to Cash Flow -2.68

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.